Calliditas Therapeutics AB
Calliditas Therapeutics is a specialty pharmaceutical company focused on developing high value medical products for patients with significant unmet medical needs in niche indications, where the company can partially or completely participate in the commercialization.
Calliditas is focused on the development and commercialization of its lead product candidate Nefecon, which has successfully completed a Phase 2b clinical trial, as a potential new treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure.